RT Journal Article
T1 Concordance between serum and cytosolic levels of CEA CA125 and SCC antigens in patients with non-small cell lung cancer
A1 Díez, Manuel
A1 Pollan, Marina
A1 Maestro, Maria Luisa
A1 Ortega, Maria Dolores
A1 Gómez Martínez, Ana María
A1 Sánchez Pernaute, Andrés
A1 Torres García, Antonio José
A1 Granell, Javier
A1 Balibrea Cantero, José Luis
AB The relationship between serum and cytosolic levels of carcinoembryonic (CEA), squamous - cell carcinoma (SCC) and CA125 antigens was determined in 122 patients with nonsmall cell lung cancer. A pronounced serum-cytosol gradient and a high degree of dispersion in the distribution of serum and cytosol marker concentrations was detected. In addition the degree of concordance between TM levels in the two compartments, determined by the intraclass correlation coefficient (ICC) index, was low (ICC = 0.42 for CEA; 0.35 for CA125; and 0.27 for SCC). Tumour stage and histological type both played a limited role in the serum-cytosol relationship. As tumour stage advanced the concordance between serum and cytosolic TM level became more pronounced In addition, each histological type showed a distinctive pattern of expression of serum and cytosolic tumour markers, and a specific degree of concordance between levels in serum and cytosol. However the ICC indices were always under 0.51, indicating that the importance of these factors is minor. The data obtained indicate that the relationship between serum and cytosolic concentration is moderate. The differences found according to stage grouping and histological subtype are so small that no clear-cut message for clinical practice can be drawn.
PB INT INST ANTICANCER RESEARC
SN 0250-7005
YR 1995
FD 1995
LK https://hdl.handle.net/20.500.14352/116265
UL https://hdl.handle.net/20.500.14352/116265
LA eng
NO Diez M, Pollan M, Maestro ML, Ortega MD, Gomez A, Sanchez-Pernaute A, Torres A, Granell J, Balibrea JL. Concordance between serum and cytosolic levels of CEA, CA125 and SCC antigens in patients with non-small cell lung cancer. Anticancer Res. 1995 Nov-Dec;15(6B):2811-7. PMID: 8669870.
DS Docta Complutense
RD 10 abr 2025